6 JULY-AUGUST 2025APACRegenerative medicine is rapidly transitioning from experimental therapy to a cornerstone of modern healthcare in the Asia-Pacific region. From Japan's cutting-edge cell therapies to Australia's pioneering tissue engineering and Singapore's dynamic biotech ecosystem, APAC is emerging as a global hub for innovation in this transformative field. These advancements are enabling healthcare providers to address conditions once deemed untreatable, ranging from neurodegenerative disorders to complex orthopedic injuries.Driven by the growing demand for personalized, minimally invasive solutions, regenerative treatments are gaining momentum across public and private healthcare systems. Governments and institutions across the region are ramping up investments in clinical infrastructure, streamlining regulatory frameworks and fostering international partnerships to bring these therapies to patients faster. This surge of activity is also propelling a new generation of startups and biotech firms focused on stem cell research, gene editing and biologics tailored to APAC's diverse populations. As regenerative medicine moves from the lab to the bedside, the focus is shifting toward real-world outcomes, equitable access and sustainable delivery models--ushering in a new era of patient-centered innovation across the region.This edition of Healthcare Business Review APAC explores the quiet but powerful integration of regenerative medicine into mainstream healthcare across the region. What began as niche research is now influencing clinical protocols, investment strategies and national health priorities. From evolving therapies to supportive policy shifts, the transformation is reshaping how care is delivered and what patients can expect from the future of medicine.The cover story features Neurotech Medical, a company at the forefront of regenerative treatment development. Combining cutting-edge autologous stem cell therapy with targeted neuromodulation and precision rehabilitation, Neurotech is redefining recovery for patients with neurological damage. With a strong R&D foundation and a clear clinical focus, the company is setting new benchmarks for innovation in APAC's medtech landscape.We hope this edition offers valuable perspective on the innovations, challenges and opportunities shaping regenerative medicine across the Asia-Pacific region. As the field continues to evolve, we aim to inspire fresh thinking, create collaboration and support new approaches that move the industry and patient care forward.Let us know your thoughts!Alex D'souzaManaging Editoreditor@healthcarebusinessreview.comChanging the Face of Medicine with Regenerative TherapiesEditorialManaging EditorAlex D'souzaEditorial StaffAaron PaulGina ClumskyJoe PhillipJames SmithMark RobertYenny TurnerCopyright © 2025 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Email:sales@healthcarebusinessreview.comeditor@healthcarebusinessreview.commarketing@healthcarebusinessreview.comVisualizersVictor CruzEdwin PaulJULY-AUGUST 2025, volume 08 - Issue 17 Published by ValleyMedia, Inc. (ISSN 2836-7030)To subscribe to Healthcare Business ReviewVisit www.healthcarebusinessreview.com Disclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsAPAC
< Page 5 | Page 7 >
< Page 5 | Page 7 >